MetaVia

MetaVia P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of MetaVia (MTVA) as of Oct 30, 2026 is -0.35. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -0.22 — a change of 57.41% (lower).

P/FCF

-0.35

YoY

57.41%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of MetaVia is 2025 -0.35 . P/FCF (Price-to-Free-Cash-Flow Ratio) of MetaVia was 2024 -0.22 . It decreases by 57.41% lower compared to the previous year.

The MetaVia P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
-0.38 USD
Jan 1, 2019
-0.75 USD
Jan 1, 2020
-0.50 USD
Jan 1, 2021
-0.36 USD
Jan 1, 2022
-0.46 USD
Jan 1, 2023
-0.50 USD
Jan 1, 2024
-0.22 USD
Jan 1, 2025
-0.35 USD
The MetaVia P/FCF history
YEARP/FCFYoY
-0.35+57.41%
-0.22-56.11%
-0.50+7.95%
-0.46+29.24%
-0.36-28.86%
-0.50-32.64%
-0.75+99.28%
-0.38+86.11%
-0.20-58.95%
-0.49-50.80%
-1.00-96.41%
-27.88—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MetaVia Stock analysis

What does MetaVia do? NeuroBo Pharmaceuticals, Inc. generates revenue by developing novel pharmaceuticals to address unmet medical needs in patients suffering from neurodegenerative disorders. The company focuses on specific therapeutic areas including Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease, targeting these conditions with its proprietary product candidates. This strategy allows the firm to serve the clinical-stage biotechnology market by offering specialized treatments for serious health conditions. The company’s product portfolio includes NB-01, which is designed to target neuropathic pain with an indication for PDN, and NB-02, a drug developed for Alzheimer’s and tauopathies. Additionally, the firm offers Gemcabene, a therapy focused on treating dyslipidemia, a condition that increases the risk of life-threatening cardiovascular disease. Gemcabene is specifically directed at orphan indications such as homozygous familial hypercholesterolemia (HoFH) and severe hypertriglyceridemia (SHTG). Furthermore, NeuroBo Pharmaceuticals, Inc. is developing a capsule formulation of niclosamide for coronavirus indications. By expanding its research into these diverse medical conditions, the company aims to provide comprehensive pharmaceutical solutions. The firm operates from its headquarters in Boston, Massachusetts, and maintains a focused development pipeline to bring these treatments to market. MetaVia is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MetaVia stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of MetaVia is -0.35 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of MetaVia changed from -0.22 to -0.35, representing a 57.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) MetaVia since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s MetaVia with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — MetaVia

All Key Metrics — MetaVia